Apogossypolone (ApoG2) is primarily investigated for its potential in cancer therapy. It is known to inhibit the activity of Bcl-2 family proteins, which play a crucial role in regulating apoptosis, or programmed cell death. By targeting these proteins, Apogossypolone can induce apoptosis in cancer cells, making it a promising candidate for treating various types of cancers, including leukemia, lymphoma, and solid tumors. Additionally, it has shown efficacy in overcoming drug resistance in certain cancer cells, enhancing the effectiveness of conventional chemotherapy. Research is ongoing to explore its full therapeutic potential and to develop it as a part of combination therapies for improved cancer treatment outcomes.